1. Home
  2. NUVB

as 09-05-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 837.0M IPO Year: N/A
Target Price: $8.00 AVG Volume (30 days): 5.9M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.63 EPS Growth: N/A
52 Week Low/High: $1.54 - $4.09 Next Earning Date: 11-05-2025
Revenue: $14,355,000 Revenue Growth: 900.35%
Revenue Growth (this year): 332.8% Revenue Growth (next year): 360.12%

NUVB Daily Stock ML Predictions

Share on Social Networks: